MARKET

ASMB

ASMB

Assembly
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.480
-0.150
-3.24%
After Hours: 4.500 +0.02 +0.45% 19:50 03/05 EST
OPEN
4.640
PREV CLOSE
4.630
HIGH
4.660
LOW
4.305
VOLUME
2.64M
TURNOVER
--
52 WEEK HIGH
27.84
52 WEEK LOW
4.305
MARKET CAP
171.34M
P/E (TTM)
-2.5177
1D
5D
1M
3M
1Y
5Y
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Mar 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc....
GlobeNewswire · 1d ago
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 4)
Benzinga · 1d ago
Microbiome Therapeutics Market 2021 Global Market Research report covers a detailed study of the Market size, growth, and share, trends, consumption, segments, application and Forecast 2026.
The Express Wire · 3d ago
Assembly Biosciences (ASMB) Gets a Buy Rating from Leerink Partners
SmarterAnalyst · 4d ago
DJ Assembly Biosciences, Inc. CEO on Hepatitis B Program Update Call Transcript >ASMB
Dow Jones · 6d ago
Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection
Benzinga · 02/26 16:52
The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25)
Benzinga · 02/26 13:16
Assembly Bio, Arbutus Bio commence trial of triple combo therapy in hepatitis B
Assembly Biosciences (ASMB) and Arbutus Biopharma (ABUS) have initiated a Phase 2 clinical trial of Assembly Bio’s investigational capsid inhibitor, vebicorvir ((VBR)), in combination with Arbutus’ GalNAc delivered RNAi therapeutic
Seekingalpha · 02/26 12:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASMB. Analyze the recent business situations of Assembly through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASMB stock price target is 11.60 with a high estimate of 15.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 196
Institutional Holdings: 29.14M
% Owned: 76.19%
Shares Outstanding: 38.25M
TypeInstitutionsShares
Increased
39
5.95M
New
65
-5.52M
Decreased
25
3.82M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
William Ringo
President/Chief Executive Officer/Director
John McHutchison
Chief Financial Officer
Thomas Russo
Chief Financial Officer
Thomas Joseph Russo
Senior Vice President/Chief Scientific Officer
Jacqueline Papkoff
Senior Vice President
David Houck
Senior Vice President
Steven Knox
Senior Vice President
Nicole White
Chief Scientific Officer
William Delaney
Other
Jason Okazaki
Other
Luisa Stamm
Independent Director
Anthony Altig
Independent Director
Gina Consylman
Independent Director
Richard DiMarchi
Independent Director
Myron Holubiak
Independent Director
Susan Mahony
No Data
About ASMB
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Webull offers kinds of Assembly Biosciences Inc stock information, including NASDAQ:ASMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASMB stock methods without spending real money on the virtual paper trading platform.